ReviewJournal of nanobiotechnology2026
Platinum nanozymes pursue cellular redox homeostasis: playing dual roles as pro-oxidants and antioxidants.
Review in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Cellular redox homeostasis, essential for physiological integrity, is disrupted by pathological oxidative stress from imbalanced reactive oxygen species (ROS) metabolism, which is a central driver of degenerative, inflammatory diseases and tumors. Platinum (Pt) nanozymes have emerged as promising therapeutic agents capable of mimicking both antioxidative and pro-oxidative enzymatic activities, owing to their partially filled d-orbitals and accessible multivalent states, thereby enabling precise regulation of cellular redox homeostasis. From a chemical perspective, this “smart switching” capability originates from dynamic changes in microenvironmental cues, such as nanozyme concentration, H2O2 levels, and pH, which alter the dominant enzymatic activity, thereby achieving dual-mode ROS regulation by toggling between antioxidative and pro-oxidative states. This adaptive duality directly addresses a fundamental therapeutic dilemma: selectively restoring redox homeostasis in diseased tissue while sparing healthy cells. Therefore, this review systematically elaborates, for the first time, an integrated framework encompassing the intrinsic redox enzymatic activities of Pt nanozymes and their “smart switching” mechanisms, offering a cross-disciplinary perspective spanning material design to disease applications. First, we delineate evolving research trends and recent advancements in Pt nanozymes for redox homeostasis regulation through a bibliometric analysis of 512 publications from the Web of Science. Subsequently, we elucidate the catalytic mechanisms governing their tunable redox enzymatic activities and discuss versatile engineering strategies for tailoring antioxidant/pro-oxidant functionalities to enable precision therapeutic interventions. Finally, we critically evaluate current translational challenges and present future perspectives on addressing multifaceted disease pathologies using Pt nanozymes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.